Shanghai Heartcare Medical Technology Co., LTD SUCCESSFULLY LISTED ON HKEX
Latest Update:
20 th August, 2021

On August 20, 2021, the Chinese nerve involvement in medical equipment market leader ─ ─ Shanghai Heartcare Medical Technology Co., LTD (" Heartcare "or the" company ", stock code: 6609), this morning on the stock exchange of Hong Kong limited (" the Hong Kong stock exchange ") motherboard officially listed for trading, each business unit to 50 stocks.

The sale of 6,601,850 shares, of which 5,941,650 shares were offered internationally; The remaining 660,200 shares were made available for sale in Hong Kong. The Hong Kong Public Offer portion was well received with a total of 219,900,000 shares subscribed, representing approximately 333.14 times the 660,200 shares available for sale in Hong Kong.

As the financial and public relations consultant team of the company, Porda Havas has been fully involved in the maintenance of domestic and foreign media relations, the design and production of listing publicity materials, and the holding of listing celebration activities during the process of the company's listing, which helped the company to successfully go public in Hong Kong.

Heartcare chairman and chief executive officer and executive director Mr Guo-hui wang said: "we would like to thank the investors of ecg junwei medical support from all walks of life, enable the company's global sales to achieve ideal, fully show the height of the market strength to the company. Their trust, not only add to our strength and confidence in the international capital market, more challenge drives our endeavor, In the coming days to create a better performance. Heartcare will be listed as an opportunity to improve nerve involved in medical equipment market leader in China market position, we will carry on for all patients, regardless of their race, age, and the ability to pay, to provide available medical equipment and service concept, to meet the needs of stroke patients differ in thousands ways, We will also create greater value for Heartcare's shareholders and investors."

About Shanghai Heartcare Medical Technology Co., LTD

Established in 2016, Shanghai Heartcare Medical Technology Co., Ltd. is a pioneer of neurointerventional medical devices in China with the goal of redefining the treatment and prevention of stroke. With a combination of r&d, manufacturing and commercialization capabilities, Shanghai Heartcare is committed to reducing stroke mortality and improving prognosis in China and globally by commercializing innovative in-development products. Shanghai Heartcare has a one-stop product portfolio covering stroke prevention to treatment, covering the entire large, rapidly growing and very underpenetrated neurointerventional market to meet the differentiated clinical needs of stroke patients. The company is the first domestic medical device company to commercialcomplete stent thrombectomy product set. It has seven approved products and 16 products in development in China, including the world's first rapamycin intracranial drug-eluting balloon catheter for intracranial artery stenosis and other innovative medical devices.

Latest Update:
20 th August, 2021